Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · EyePoint, Inc. (EYPT)

EyePoint's LUCIA Phase 3 trial misses primary endpoint for DURAVYU in wet AMD

Negative Impact 4 of 5 other Written later

EyePoint reported topline results from LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet AMD, which did not meet its primary endpoint of statistical non-inferiority in mean change in best-corrected visual acuity versus on-label aflibercept. The company said several key secondary endpoints were met, and it will run additional analyses of LUCIA and the pooled Phase 3 data to assess next steps for wet AMD, while the DME program continues.

Key points

  • LUCIA did not meet its primary endpoint; the presentation shows a mean BCVA change of +2.5 letters for DURAVYU versus +6.1 letters for aflibercept, a difference of -3.7 letters (preliminary data).
  • LUCIA enrolled 475 patients; DURAVYU achieved a 38% reduction in treatment burden (nominal p-value below 0.0001) and 52% of eyes were supplement-free up to Week 56.
  • EyePoint will complete additional analyses of LUCIA and the pooled Phase 3 datasets to assess next steps for DURAVYU in wet AMD.
  • Pivotal Phase 3 DME topline data are anticipated in the fourth quarter of 2027.

The filing

CompanyEyePoint, Inc. (EYPT)
Form8-K, current report
Filed with the SECOct 19, 2026, 7:05 AM ET
Accession number0001193125-26-424644

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.